Angioimmunoblastic T-Cell Lymphoma AITL — Specialist Diagnosis & Care
AITL is a biologically distinct aggressive T-cell lymphoma arising from T-follicular helper cells, characterised by prominent immune dysregulation, distinctive molecular mutations, and complex management. Accurate diagnosis and molecularly informed treatment at a specialist lymphoma centre are essential to optimise outcomes.
- TFH-Origin — Molecularly Distinct Lymphoma
- IDH2 Inhibitors Emerging as Targeted Option
- BV-CHP Frontline Approved
- Expert Second Opinion Strongly Advised
- Proportion of All PTCL
- ~15–20%
- Median Age at Diagnosis
- ~65 years
- Key Molecular Driver
- RHOA G17V (~70%)
- IDH2 R172 Mutation Prevalence
- ~20–30%
- Advanced Therapies
- BV-CHP, IDH2 Inhibitors, Transplant
Condition Overview
Angioimmunoblastic T-cell lymphoma (AITL) is one of the most common subtypes of peripheral T-cell lymphoma (PTCL), accounting for approximately 15–20% of all PTCL globally. It arises from T-follicular helper cells (TFH cells) — a specialised subset of CD4-positive T cells that normally reside in germinal centres and support B-cell maturation and antibody production. This TFH cell of origin explains many of the distinctive clinical and pathological features of AITL.
The 2022 WHO classification reorganised AITL and related entities under the broader category of nodal T-follicular helper cell lymphomas (nTFHL), reflecting their shared TFH origin. Classic AITL is now termed nTFHL-AITL type. Related entities — nTFHL-follicular type and nTFHL-NOS — share overlapping biology and may require expert haematopathological distinction.
AITL is biologically unusual among lymphomas in several respects: it is characterised by a profoundly dysregulated immune microenvironment, with prominent expansion of follicular dendritic cell meshworks, high endothelial venule proliferation, polyclonal B-cell hyperplasia, and frequent co-occurrence of EBV-positive immunoblasts in the tumour microenvironment. This immune activation drives many of AITL's distinctive clinical features — including hypergammaglobulinaemia, autoimmune haemolytic anaemia, rash, arthritis, and effusions — which can initially suggest a non-malignant inflammatory condition.
Molecularly, AITL is characterised by recurring mutations in epigenetic regulators (TET2, DNMT3A, IDH2) and in the RHOA gene (the G17V hotspot mutation is present in approximately 70% of cases), providing potential therapeutic targets.
Types and Subtypes
Under the 2022 WHO classification, AITL is formally designated as nodal T-follicular helper cell lymphoma, AITL type (nTFHL-AITL). It is part of a spectrum of TFH-origin nodal lymphomas. Molecular and morphological variants within AITL influence prognosis and therapy selection.
Symptoms and Signs
AITL is distinctive for the frequency and prominence of immune-mediated and constitutional symptoms, often preceding or accompanying the lymphoma presentation. The combination of systemic inflammation and lymphadenopathy in an older adult is a characteristic clinical picture that should prompt consideration of AITL.
Causes and Risk Factors
AITL arises from malignant transformation of T-follicular helper cells, driven by an accumulation of epigenetic and signalling mutations. There are no established environmental or lifestyle risk factors. The high prevalence of TET2 and DNMT3A mutations suggests that clonal haematopoiesis (CHIP) in haematopoietic progenitors may precede and contribute to lymphomagenesis in many cases.
Diagnosis and Investigations
AITL diagnosis requires an adequate excisional lymph node biopsy with expert haematopathological evaluation. The characteristic histological features — expanded follicular dendritic cell meshworks, high endothelial venule proliferation, TFH-marker-positive neoplastic T cells, and EBV-positive immunoblasts — combined with molecular testing (RHOA G17V, IDH2, TET2 mutations) establish the diagnosis. Exclusion of reactive causes and other lymphoma types is essential.
Staging and Risk Stratification
AITL is staged using the Lugano Classification (modified Ann Arbor). The majority of patients present with advanced-stage disease (Stage III–IV) at diagnosis. The PIT score and IPI provide clinical risk stratification, and IDH2 R172 mutation status adds molecular prognostic information.
Standard Treatment
AITL treatment follows the broader PTCL treatment paradigm, centred on BV-CHP frontline immunochemotherapy (for CD30-expressing cases) or CHOP-based induction, followed by consolidation with auto-SCT in responding fit patients. The immune dysregulation of AITL complicates management and requires careful supportive care alongside anti-lymphoma treatment.
Advanced and Emerging Therapies
AITL's distinctive molecular profile — particularly IDH2 R172 mutations and the epigenetic regulator mutations (TET2, DNMT3A) — provides rational targets for novel agents. Epigenetic-targeted therapy and IDH2 inhibition are the most clinically advanced emerging approaches. CancerFax assists patients in identifying access to these options globally.
Antibody-Drug Conjugate (ADC)
Brentuximab Vedotin (BV-CHP) — CD30-Expressing AITL
BV-CHP is the current frontline standard for CD30-positive PTCL including AITL cases with CD30 expression (~50–60%). Approved based on ECHELON-2 trial data. CD30 expression in AITL should be assessed by IHC to confirm eligibility for BV-CHP versus CHOP.
IDH2 Inhibitor
Enasidenib — IDH2 R172-Mutant AITL
Enasidenib is an oral IDH2 inhibitor approved for IDH2-mutant AML. In AITL with IDH2 R172 mutations (~20–30% of cases), enasidenib has demonstrated responses including complete remissions in published case series and small studies. IDH2 R172 is a distinct mutation from IDH2 R140 in AML, but shares sensitivity to IDH2 inhibition. Formal Phase II/III studies in IDH2-mutant AITL/nTFHL are ongoing.
Hypomethylating Agent
Azacitidine — Epigenetic Targeting
Azacitidine, a DNA hypomethylating agent, targets the epigenetic driver mutations (TET2, DNMT3A) that are highly prevalent in AITL. Single-agent and combination (azacitidine + CHOP) studies have shown activity in AITL. An ongoing clinical trial (ORACLE trial and others) is formally evaluating azacitidine-based regimens in AITL.
HDAC Inhibitor
Romidepsin / Belinostat
HDAC inhibitors romidepsin (approved for PTCL) and belinostat (approved for PTCL) have activity in relapsed/refractory AITL. They target the epigenetic dysregulation underlying AITL and may work synergistically with hypomethylating agents. Used in salvage settings or combination trials.
PI3K Inhibitor
Copanlisib / Duvelisib
PI3K inhibitors have activity in relapsed/refractory PTCL including AITL, reflecting the frequent PI3K pathway activation in these tumours. Duvelisib (PI3K-delta/gamma inhibitor) received accelerated FDA approval for relapsed/refractory follicular lymphoma and has been studied in PTCL. Clinical trial evaluation in AITL is ongoing.
Autologous / Allogeneic Stem Cell Transplantation
SCT Consolidation — Auto in CR1, Allo in CR2
Auto-SCT in CR1 is the standard consolidation for fit AITL patients achieving remission with induction. Allo-SCT in CR2 or for high-risk patients offers graft-versus-lymphoma benefit and the best prospect for durable remission in relapsed/refractory disease. Reduced-intensity conditioning extends eligibility to older patients with adequate performance status.
China Access — Epigenetic and Novel Trials
IDH2 and Epigenetic Combination Programmes in China
Leading Chinese haematology centres (Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, Huashan Hospital) have active PTCL research including AITL-specific epigenetic therapy studies. CancerFax facilitates patient coordination for IDH2 inhibitor, azacitidine, and combination trial access at these centres.
Biomarkers and Precision Medicine
Molecular profiling in AITL has revealed a rich landscape of actionable and prognostic mutations. The combination of high-prevalence epigenetic mutations (TET2, DNMT3A), the near-diagnostic RHOA G17V, and the therapeutically targetable IDH2 R172 makes comprehensive NGS panel testing essential in all AITL patients.
When to Seek a Second Opinion
AITL is frequently misdiagnosed initially and requires expert haematopathology for accurate classification and molecular subtyping. The complexity of treatment decisions — BV-CHP versus CHOP, IDH2 inhibitor eligibility, transplant planning — benefits substantially from specialist T-cell lymphoma team input.
Clinical Trials and Research in AITL
Prognosis and Outcomes
AITL has a worse prognosis than many other lymphoma types, with most patients presenting at advanced stage and older age. However, outcomes are heterogeneous — a subset of patients with favourable risk features and access to expert care and transplant consolidation achieve durable remission. Emerging targeted therapies offer new hope for the IDH2-mutant subgroup.
Supportive Care
AITL's distinctive immune dysregulation creates supportive care challenges that go beyond those of other lymphomas. Managing autoimmune complications, infection risk from immune dysfunction, and treatment toxicity requires an experienced multidisciplinary team.
How CancerFax Helps You Explore Treatment Options
CancerFax supports patients with AITL by facilitating expert haematopathology review including TFH marker and molecular testing, identifying IDH2 mutation status for targeted therapy eligibility, coordinating specialist PTCL second opinions and transplant consultations, and assisting with access to IDH2 inhibitor trials and epigenetic therapy programmes in India, China, and internationally.
Get a free case reviewFrequently Asked Questions
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive T-cell lymphoma arising from T-follicular helper cells that live in the germinal centres of lymph nodes. It is frequently diagnosed late because its symptoms — fever, skin rash, joint pain, high immunoglobulin levels, and autoimmune haemolytic anaemia — closely mimic inflammatory, autoimmune, or infectious conditions. Many patients receive treatment for suspected viral infections, drug reactions, or autoimmune diseases before a lymph node biopsy reveals the underlying AITL. A high index of clinical suspicion and early haematology referral are essential for timely diagnosis.
The T-follicular helper (TFH) cell origin of AITL explains its biology and clinical features — the tumour cells drive the immune dysregulation (B-cell expansion, autoantibodies, hypergammaglobulinaemia) that characterises the disease. The TFH origin also provides biological rationale for targeting epigenetic pathways (TET2, DNMT3A, IDH2 mutations are highly prevalent) and immune checkpoint pathways that are important in germinal centre biology. The WHO 2022 classification now formally groups AITL under nodal T-follicular helper cell lymphomas (nTFHL), reflecting the shared TFH origin.
IDH2 R172 mutations are found in approximately 20–30% of AITL cases. Unlike the IDH2 R140 mutations common in AML, IDH2 R172 mutations in AITL generate the oncometabolite 2-hydroxyglutarate in a way that profoundly disrupts DNA and histone methylation, driving lymphoma growth. Importantly, IDH2 inhibitors — particularly enasidenib — have shown clinical responses including complete remissions in published IDH2 R172-mutant AITL cases. Formal clinical trials are underway. Identification of this mutation by NGS should prompt referral for IDH2 inhibitor trial eligibility assessment.
Azacitidine is a hypomethylating agent (HMA) that inhibits DNA methyltransferase activity, reversing the aberrant DNA methylation caused by TET2 and DNMT3A mutations — which are present in approximately 80% and 20–30% of AITL cases respectively. By targeting this epigenetic vulnerability, azacitidine may preferentially affect AITL tumour cells while having acceptable toxicity. Several investigator-initiated studies and one larger cooperative trial (ORACLE) are evaluating azacitidine in combination with chemotherapy in AITL frontline and relapsed settings. Early results support further investigation.
EBV-positive B-cell immunoblasts are characteristically present in the tumour microenvironment of the majority of AITL cases. These EBV-positive cells are not the primary lymphoma cells — the tumour itself consists of malignant T-cells — but they contribute to the inflammatory microenvironment that supports tumour growth. During immunochemotherapy, impaired immune surveillance can allow EBV-positive B cells to expand, causing EBV reactivation or, rarely, transformation to an EBV-positive diffuse large B-cell lymphoma. EBV viral load monitoring and prompt management of EBV reactivation are important aspects of AITL supportive care.
Auto-SCT consolidation in first complete remission is recommended for fit patients with AITL who respond to frontline induction therapy, based on PTCL registry data showing improved progression-free survival with transplant consolidation. However, given the older median age at AITL diagnosis (approximately 65 years), many patients have comorbidities or performance status limitations that preclude transplant. For these patients, full-course chemotherapy without transplant or reduced-intensity regimens are used. Transplant eligibility and conditioning intensity should be assessed at a specialist PTCL transplant centre.
Relapsed or refractory AITL requires repeat biopsy to confirm relapse, reassess CD30 and IDH2 status, and identify any clonal evolution. Key salvage options include: IDH2 inhibitors (enasidenib) for IDH2 R172-mutant disease (clinical trial access preferred); HDAC inhibitors (romidepsin, belinostat, approved for PTCL); azacitidine (epigenetic targeting, active in AITL); BV monotherapy for CD30-positive relapse in non-BV-treated patients; and allo-SCT in CR2 for eligible younger patients. Clinical trial enrolment is the preferred path for all fit relapsed/refractory patients.
Yes. CancerFax supports patients with AITL by reviewing pathology reports and molecular panels, confirming IDH2 and RHOA mutation status, identifying BV-CHP eligibility and IDH2 inhibitor trial access, coordinating second opinions with specialist haematopathologists and T-cell lymphoma oncologists, and facilitating access to epigenetic therapy programmes and transplant evaluations at leading centres in India, China, and internationally. Please share your medical reports through the CancerFax portal or contact our team to begin.
Facing AITL? CancerFax Connects You With Specialist Expertise.
From accurate molecular diagnosis and IDH2 mutation testing to BV-CHP access, transplant planning, and epigenetic trial enrolment, CancerFax helps AITL patients navigate complex treatment decisions and access specialist PTCL care globally.